Kolon Life Science Inc Total Liabilities
Kolon Life Science Inc total liabilities. Based on the latest financial reports, Kolon Life Science Inc (102940) has total liabilities worth ₩295.72 Billion KRW (≈ $200.41 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check 102940 cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Kolon Life Science Inc (2014–2024)
Total liabilities of Kolon Life Science Inc from 2014 to 2024. This chart illustrates how Kolon Life Science Inc's total liabilities have evolved over time, based on quarterly financial data. Explore 102940 long-term investments to assets to see how much of total assets are deployed in long-term investments.
Kolon Life Science Inc Competitors by Total Liabilities
The table below lists competitors of Kolon Life Science Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Nicola Mining Inc. American Depositary Shares
NASDAQ:NICM
|
USA | $15.95 Million |
|
Patriot National Bancorp Inc
NASDAQ:PNBK
|
USA | $1.23 Billion |
|
KEYEAST.Co.Ltd
KQ:054780
|
Korea | ₩19.16 Billion |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩238.21 Billion |
|
DATA MODUL Aktiengesellschaft Produktion und Vertrieb von elektronischen Systemen
XETRA:DAM
|
Germany | €54.11 Million |
|
Logistic Properties of the Americas
NYSE MKT:LPA
|
USA | $376.20 Million |
|
Kewaunee Scientific Corporation
NASDAQ:KEQU
|
USA | $98.58 Million |
|
Samick Thk
KO:004380
|
Korea | ₩257.11 Billion |
Liability Composition Analysis (2014–2024)
This chart breaks down Kolon Life Science Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Kolon Life Science Inc asset portfolio.
Liquidity & Leverage Metrics
Kolon Life Science Inc Total Liabilities Ratios Explained
Kolon Life Science Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.56 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.85 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.46 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Kolon Life Science Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Kolon Life Science Inc (2014–2024)
The table below shows the annual total liabilities of Kolon Life Science Inc from 2014 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩270.23 Billion ≈ $183.13 Million |
+57.32% |
| 2023-12-31 | ₩171.76 Billion ≈ $116.40 Million |
+17.33% |
| 2022-12-31 | ₩146.39 Billion ≈ $99.21 Million |
+8.24% |
| 2021-12-31 | ₩135.25 Billion ≈ $91.66 Million |
-28.96% |
| 2020-12-31 | ₩190.38 Billion ≈ $129.02 Million |
+7.39% |
| 2019-12-31 | ₩177.27 Billion ≈ $120.14 Million |
+2.61% |
| 2018-12-31 | ₩172.76 Billion ≈ $117.08 Million |
+0.80% |
| 2017-12-31 | ₩171.38 Billion ≈ $116.14 Million |
+80.81% |
| 2016-12-31 | ₩94.78 Billion ≈ $64.23 Million |
+1.73% |
| 2015-12-31 | ₩93.17 Billion ≈ $63.14 Million |
+28.13% |
| 2014-12-31 | ₩72.72 Billion ≈ $49.28 Million |
-- |
About Kolon Life Science Inc
Kolon Life Science Inc. provides biopharmaceuticals, active pharmaceutical ingredients, pyrithione antimicrobials, and water solutions primarily in South Korea. Its biopharmaceutical product under development comprise KLS-1020, a cancer vaccine; KLS-3021, a oncolytic viral therapy; and KLS-2031 for treatment for neuropathic pain. The company also provides active pharmaceutical ingredients for ant… Read more